Chitosan-Stabilized Selenium Nanoparticles Alleviate High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease (NAFLD) by Modulating the Gut Barrier Function and Microbiota

Overview

Journal J Funct Biomater

Specialty Biomedical Engineering

Date 2024 Aug 28

PMID 39194674

Authors

Yuhang Luo

Shujiang Peng

Jintao Cheng

Hongli Yang

Lin Lin

Guiling Yang

Yuanxiang Jin

Qingchi Wang

Zhengshun Wen

Affiliations

Soon will be listed here.

Abstract

Low molecular weight chitosan selenium nanoparticles (LCS-SeNPs), a biologically active compound derived from selenium polysaccharides, have demonstrated potential in addressing obesity. However, the mechanism through which LCS-SeNPs alleviate high-fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) remains unclear. Our results elucidated that LCS-SeNPs significantly inhibited fat accumulation and markedly improved the intestinal barrier by increasing mucus secretion from goblet cells. Moreover, LCS-SeNPs reshaped intestinal flora composition by increasing the abundance of mucus-associated microbiota (, , and ) and decreasing the abundance of obesity-contributed bacterium (, , and ). The modulation of intestinal microbiota by LCS-SeNPs influenced several metabolic pathways, including bile acid secretion, purine metabolites, and tryptophan derivation. Meanwhile, glycocholic acid and tauro-beta-muricholic acid were significantly reduced in the LCS-SeNP group. Our study suggests the crucial role of intestinal microbiota composition and metabolism, providing a new theoretical foundation for utilizing selenium polysaccharides in the intervention of HFD-induced NAFLD.

References

Feng K, Zhang H, Chen C, Ho C, Kang M, Zhu S . Heptamethoxyflavone Alleviates Metabolic Syndrome in High-Fat Diet-Fed Mice by Regulating the Composition, Function, and Metabolism of Gut Microbiota. J Agric Food Chem. 2023; 71(26):10050-10064. DOI: 10.1021/acs.jafc.3c01881. View

Wang W, Zhao J, Gui W, Sun D, Dai H, Xiao L . Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. Br J Pharmacol. 2017; 175(3):469-484. PMC: 5773980. DOI: 10.1111/bph.14095. View

He K, Gao Q, Su J, Shang H, Meng X, Jiang S . Gut Microbiome and Metabolomics Study of Selenium-Enriched Kiwifruit Regulating Hyperlipidemia in Mice Induced by a High-Fat Diet. J Agric Food Chem. 2023; 71(50):20386-20401. DOI: 10.1021/acs.jafc.3c00108. View

Peng S, Ye D, Zheng J, Xue Y, Lin L, Zhao Y . Synthesis, Characterization of Low Molecular Weight Chitosan Selenium Nanoparticles and Its Effect on DSS-Induced Ulcerative Colitis in Mice. Int J Mol Sci. 2022; 23(24). PMC: 9779469. DOI: 10.3390/ijms232415527. View

He N, Wang S, Lv Z, Zhao W, Li S . Low molecular weight chitosan oligosaccharides (LMW-COSs) prevent obesity-related metabolic abnormalities in association with the modification of gut microbiota in high-fat diet (HFD)-fed mice. Food Funct. 2020; 11(11):9947-9959. DOI: 10.1039/d0fo01871f. View

Wang J, Han L, Liu Z, Zhang W, Zhang L, Jing J . Genus unclassified_Muribaculaceae and microbiota-derived butyrate and indole-3-propionic acid are involved in benzene-induced hematopoietic injury in mice. Chemosphere. 2022; 313:137499. DOI: 10.1016/j.chemosphere.2022.137499. View

Fan Y, Pedersen O . Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2020; 19(1):55-71. DOI: 10.1038/s41579-020-0433-9. View

Ran Q, Gan Q, Zhu Y, Song L, Shen L, Duan X . Mechanism insights into the pleiotropic effects of nobiletin as a potential therapeutic agent on non-alcoholic fatty liver disease (NAFLD). Biomed Pharmacother. 2024; 173:116322. DOI: 10.1016/j.biopha.2024.116322. View

Ekstedt M, Franzen L, Mathiesen U, Thorelius L, Holmqvist M, Bodemar G . Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44(4):865-73. DOI: 10.1002/hep.21327. View

10.

Paone P, Suriano F, Jian C, Korpela K, Delzenne N, Van Hul M . Prebiotic oligofructose protects against high-fat diet-induced obesity by changing the gut microbiota, intestinal mucus production, glycosylation and secretion. Gut Microbes. 2022; 14(1):2152307. PMC: 9715274. DOI: 10.1080/19490976.2022.2152307. View

11.

Rao A, Kosters A, Mells J, Zhang W, Setchell K, Amanso A . Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice. Sci Transl Med. 2016; 8(357):357ra122. PMC: 5056562. DOI: 10.1126/scitranslmed.aaf4823. View

12.

Li H, Xi Y, Xin X, Tian H, Hu Y . Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota-bile acid-farnesoid X receptor axis. Biomed Pharmacother. 2020; 124:109915. DOI: 10.1016/j.biopha.2020.109915. View

13.

Jiao N, Baker S, Chapa-Rodriguez A, Liu W, Nugent C, Tsompana M . Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut. 2017; 67(10):1881-1891. DOI: 10.1136/gutjnl-2017-314307. View

14.

Wang R, Fan X, Lu Y, Chen D, Zhao Y, Qi K . Dietary acetic acid suppress high-fat diet-induced obesity in mice by altering taurine conjugated bile acids metabolism. Curr Res Food Sci. 2022; 5:1976-1984. PMC: 9596597. DOI: 10.1016/j.crfs.2022.10.021. View

15.

Cremonini E, Wang Z, Bettaieb A, Adamo A, Daveri E, Mills D . (-)-Epicatechin protects the intestinal barrier from high fat diet-induced permeabilization: Implications for steatosis and insulin resistance. Redox Biol. 2017; 14:588-599. PMC: 5691220. DOI: 10.1016/j.redox.2017.11.002. View

16.

Grander C, Grabherr F, Spadoni I, Enrich B, Oberhuber G, Rescigno M . The role of gut vascular barrier in experimental alcoholic liver disease and A. muciniphila supplementation. Gut Microbes. 2020; 12(1):1851986. PMC: 7714498. DOI: 10.1080/19490976.2020.1851986. View

17.

Macpherson A, Harris N . Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol. 2004; 4(6):478-85. DOI: 10.1038/nri1373. View

18.

Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S . Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019; 25(7):1096-1103. PMC: 6699990. DOI: 10.1038/s41591-019-0495-2. View

19.

Wang G, Jiao T, Xu Y, Li D, Si Q, Hao J . Bifidobacterium adolescentis and Lactobacillus rhamnosus alleviate non-alcoholic fatty liver disease induced by a high-fat, high-cholesterol diet through modulation of different gut microbiota-dependent pathways. Food Funct. 2020; 11(7):6115-6127. DOI: 10.1039/c9fo02905b. View

20.

Li S, Lv H, Chen Y, Song H, Zhang Y, Wang S . N-trimethyl chitosan coated targeting nanoparticles improve the oral bioavailability and antioxidant activity of vitexin. Carbohydr Polym. 2022; 286:119273. DOI: 10.1016/j.carbpol.2022.119273. View